Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.

Front Oncol · 2022 · PMC9197581 · PMID 35712486

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an encouraging trendno p-value reported

Furthermore, patients with an AFP response exhibited an encouraging trend of greater PFS benefits than patients without an AFP response (16.3 vs. 3.6 months) (shown in online Supplementary Figure 1B ).

also in 355 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.